Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome

Overview

The purpose of this study is to determine whether Lovastatin, Minocycline and the combination Lovastatin/Minocycline are effective in treating behavioral symptoms in Fragile X individuals.

Full Title of Study: “A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2017

Interventions

  • Drug: Minocycline, then Minocycline/Lovastatin
    • Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
  • Drug: Lovastatin, then Minocycline/Lovastatin
    • Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.

Arms, Groups and Cohorts

  • Experimental: Minocycline, then Minocycline/Lovastatin
    • Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.
  • Experimental: Lovastatin, then Minocycline/Lovastatin
    • Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline Aberrant Behavior Checklist-Community (ABC-C) total score at 8,12 and 20 weeks
    • Time Frame: baseline, 8 weeks, 12 weeks, 20 weeks

Secondary Measures

  • Clinical Global Impression Scale improvement (CGI-I)
    • Time Frame: baseline, 8 weeks, 12 weeks, 20 weeks
  • Change from baseline Social Responsiveness Scale (SRS) at 8 and 20 weeks
    • Time Frame: baseline, 8 weeks, 20 weeks
  • Anxiety, depression and mood scale (ADAMS), change from baseline to 8 and 20 weeks
    • Time Frame: baseline, 8 weeks, 20 weeks
  • Behavior Rating Inventory of Executive Function (BRIEF)
    • Time Frame: Before treatment and at the end of treatment (weeks 20)
  • Change from baseline Vineland II; adaptive behaviour scale at 20 weeks
    • Time Frame: baseline, 20 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Molecular diagnosis of fragile X syndrome – The participant must be accompanied his parent, legal tutor or legal representative. – Identify a caregiver who spends at least six hours per day with the participant (may be the parent, legal tutor, legal representative or an other person). – IQ < 70 – ABC-C score > 20 – CGI-Severity score ≥ 4 Exclusion Criteria:

  • Pregnant or breastfeeding participants – Previous intolerance/allergy to statins, minocycline or tetracyclines – Participants who have taken lovastatin or minocycline in the last 12 weeks – Personal history of myopathy, myalgia or high creatine kinase (CK) levels – Renal disease / liver disease / disturbed hepatorenal tests – Participants taking more than three psychoactive medications (except anticonvulsants) – Untreated or uncontrolled hypothyroidism – Any other active medical condition – Modification of psychoactive treatment in the last 6 weeks prior to randomization – Participants under the age of 13 years who have incomplete formation of the crown of their teeth (except possibly their 3rd molars) as shown by panorex – Concomitant use of prohibited drugs – Prohibited drugs include other hypolipemic including gemfibrozil (or other fibrates) and niacin (nicotinic acid), angiotensin converting enzyme (ACE), cyclosporine, danazol, amiodarone, verapamil and inhibitors P450 (CYP3A4) (itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, inhibitors of HIV protease and nefazodone).

Gender Eligibility: All

Minimum Age: 8 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Université de Sherbrooke
  • Collaborator
    • FRAXA Research Foundation
  • Provider of Information About this Clinical Study
    • Principal Investigator: Francois Corbin, Dr Francois Corbin, MD, PHD, FRCPC – Université de Sherbrooke
  • Overall Official(s)
    • François Corbin, MD/PhD, Principal Investigator, Fragile X Clinic, Centre de recherche du CHUS

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.